305 related articles for article (PubMed ID: 29352043)
1. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
4. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
11. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.
Mohan S; Ayub M; Rothwell DG; Gulati S; Kilerci B; Hollebecque A; Sun Leong H; Smith NK; Sahoo S; Descamps T; Zhou C; Hubner RA; McNamara MG; Lamarca A; Valle JW; Dive C; Brady G
Sci Rep; 2019 Aug; 9(1):11610. PubMed ID: 31406261
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
[TBL] [Abstract][Full Text] [Related]
14. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
16. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
18. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
19. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
[TBL] [Abstract][Full Text] [Related]
20. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
